The evolution of predictive oncology and molecular-based therapy for oral cancer prevention

International Journal of Cancer

Volumn 115, Issue 3, 2005, Pages 339-345

  Sudbø, Jon ^a,b   Reith, Albrecht ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aneuploidy; Cancer prevention; Leukoplakia; Molecular based therapy; Predictive oncology; Targeted therapy

Indexed keywords

CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROTEIN KINASE C; STAT3 PROTEIN;

ANEUPLOIDY; CANCER MORTALITY; CANCER PREVENTION; CANCER SURGERY; CARCINOGENESIS; CHEMOPROPHYLAXIS; EARLY DIAGNOSIS; FOLLOW UP; GENOMIC INSTABILITY; HUMAN; LEUKOPLAKIA; MALIGNANT TRANSFORMATION; MORBIDITY; MOUTH CARCINOMA; MOUTH MUCOSA; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TARGET ORGAN;

ANEUPLOIDY; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; HUMANS; LEUKOPLAKIA, ORAL; MOUTH NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 18644365247     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20896     Document Type: Short Survey

References (79)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Mork J. Forty years of monitoring head and neck cancer in Norway - no good news. Anticancer Res 1998;18:3705-8.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
4. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
5. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691-4.
6. Boyle P, Macfarlane GJ, Scully C. Oral cancer: necessity for prevention strategies. Lancet 1993;342:1129.
7. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-10.
8. Institute for Epidemiological Cancer Research. Anonymous cancer in Norway 2000. The Cancer Registry of Norway. Oslo; Institute for Epidemiological Cancer Research, 2003.
9. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study of 3256 oral leukoplakias. Cancer 1975;36:1386-92.
10. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol 1986;61:373-81.
11. Silverman SJ, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8.
12. Silverman SJ, Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data-1973 to 1985. J Am Dent Assoc 1990;120:495-9.
13. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J. Cancer of the base of the tongue: past and future. Head Neck 1999;21:751-9.
14. Suarez P, Batsakis JG, El-Naggar AK. Leukoplakia: still a gallimaufry or is progress being made? A review. Adv Anat Pathol 1998;5:137-55.
15. Pindborg JJ, Reichart PA, Smith CJ, Waal J van der. Histological typing of cancer and precancer of the oral mucosa, 2nd ed. London: Springer, 1997.
16. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:321-9.
17. Jones AS. Prognosis in mouth cancer: tumour factors. Eur J Cancer B Oral Oncol 1994;30B:8-15.
18. Schantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997;216:275-82.
19. Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielsen HW, Dabelsteen E. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995;24:198-200.
20. Sudbø J, Bryne M, Johannessen AC, Kildal W, Danielsen HE, Reith A. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J Pathol 2001;194:303-10.
21. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 1996;56:5600-4.
22. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
23. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-62.
24. Sudbo J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8.
25. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12:82-8.
26. Gardner RD, Burke DJ. The spindle checkpoint: two transitions, two pathways. Trends Cell Biol 2000;10:154-8.
27. Ried T, Heselmeyer-Haddad K, Biegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999;25:195-204.
28. Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, Lengauer C. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics 1999;58:181-7.
29. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
30. Sudbø J, Ried T, Bryne M, Kildal W, Danielsen HE, Reith A. Abnormal DNA content predicts the occurrence of carcinomas in non-dysplastic oral white patches. Oral Oncol 2001;37:558-65.
31. Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13.
32. Sudbø J, Kildal W, Johannessen AC, Koppang HS, Sudbø A, Danielsen HE, Risberg B, Reith A. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456-62.
33. Bouquot JE, Ephros H. Erythroplakia: the dangerous red mucosa. Pract Periodont Aesthet Dent 1995;7:59-67.
34. Lippman SM, Benner SE, Hona WK. Cancer chemoprevention. J Clin Oncol 1994;12:851-73.
35. Greenspan D, Jordan RC. The white lesion that kills - aneuploid dysplastic oral leukoplakia. N Engl J Med 2004;350:1382-4.
36. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998;90:1514-28.
37. O'Shauahnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
38. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-30.
39. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
40. Jang SJ, Chiba I, Hirai A, Hong WK, Mao L. Multiple oral squamous epithelial lesions: are they genetically related? Oncogene 2001;20:2235-42.
41. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
42. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer [editorial]. N Engl J Med 2001;344:1323-6.
43. Côté RA. ed. Systematized nomenclature of medicine, 2nd ed. New York: Springer, College of American Pathologists, 1979.
44. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537-43.
45. Boardman LA. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am 2002;31:1107-31.
46. Lippman SM, Hong WK. Cancer prevention by delay. Commentary re: J.A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development (Clin Cancer Res 8:314-46. 2002). Clin Cancer Res 2002;8:305-13.
47. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119-25.
48. Sporn MB. The war on cancer: a review. Ann NY Acad Sci 1997;833:137-46.
49. Sudbø J, Ristimäki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003;39:497-505.
50. Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004;314:1093-9.
51. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003;5:140-6.
52. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998;20:320-7.
53. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
54. Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998;4:13-20.
55. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003;9:3183-9.
56. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Winner A, Nunes M, Frost P, Discafani CM. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
57. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-9.
58. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
59. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
60. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-57.
61. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res 1997;57:1081-5.
62. Zakar T, Mijovic JE, Eyster KM, Bhardwaj D, Olson DM. Regulation of prostaglandin H2 synthase-2 expression in primary human amnion cells by tyrosine kinase dependent mechanisms. Biochim Biophys Acta 1998;1391:37-51.
63. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM. De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:1566-72.
64. Chen ZG, Zhang X, Wang Z, Li M, Grandis JR, Shin DM. A possible interaction between epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) mediated pathways in squamous cell carcinoma of the head and neck (SCCHN). Proc Amer Assoc Cancer Res 2003;44:(Abst. #2242). p. 517.
65. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der NR, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004;90:224-9.
66. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004;64:1369-76.
67. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
68. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469-78.
69. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004;23:63-75.
70. Bartsch H, Nair J. Exocyclic DNA adducts as secondary markers for oxidative stress: applications in human cancer etiology and risk assessment. Adv Exp Med Biol 2001;500:675-86.
71. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
72. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62:1207-14.
73. Pang L, Nie M, Corbett L, Knox AJ. Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol 2003;170:1043-51.
74. Clay CE, Atsumi GI, High KP, Chilton FH. Early de novo gene expression is required for 15-deoxy-Delta 12, 14-prostaglandin J2-induced apoptosis in breast cancer cells. J Biol Chem 2001;276:47131-5.
75. Bartsch H. Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat Res 2000;462:255-79.
76. Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res 2004;10:1521-9.
77. Hashimoto K, Ethridge RT, Evers BM. Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer 2002;32:7-22.
78. Sudbø J. Kjemoprevensjon av munnhulekreft. Tidsskr Nor Laegeforen 2003;123:1518-21.
79. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine NNK promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004;279:40209-19.